Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9804MR)

This product GTTS-WQ9804MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9804MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15446MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ5219MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ3532MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ10002MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ11454MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ4957MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ5795MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CFZ-533
GTTS-WQ10213MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW